Abstracts tagged "outcome measures and rheumatoid arthritis"

Abstract Number: 2612 • ACR/ARHP Annual Meeting 2015
Impact of a Multibiomarker Disease Activity Score in Patients with Rheumatoid Arthritis Treated in a Real World Setting
Sergio Schwartzman¹, Keith Knapp², Gary Craig³, Karen Ferguson⁴ and Howard Kenney⁵, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Arthritis Northwest, Spokane, WA, ³Discus Analytics, Inc., Spokane, WA, ⁴Arthritis Northwest PLLC., Spokane, WA, ⁵Rheumatology, Arthritis Northwest, Spokane, WA
Background/Purpose: A number of composite outcome measures have been validated to quantify disease activity in Rheumatoid Arthritis (RA). Few studies have been published on the…
Abstract Number: 373 • ACR/ARHP Annual Meeting 2012
Patient-Reported Outcomes in Early Rheumatoid Arthritis Patients Failing to Achieve Stable Low Disease Activity: Comparing Addition of Adalimumab to Methotrexate Monotherapy with Maintenance On Adalimumab Plus Methotrexate
Arthur Kavanaugh¹, Ronald F. van Vollenhoven², Paul Emery³, James W. Shaw⁴, Mary A. Cifaldi⁵, Stefan Florentinus⁶ and Josef S. Smolen⁷, ¹UCSD School of Medicine, La Jolla, CA, ²Karolinska Institute, Stockholm, Sweden, ³Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁴Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL, ⁵Abbott Laboratories, Abbott Park, IL, ⁶AbbVie, Rungis, France, ⁷Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Treat-to-target guidelines for rheumatoid arthritis (RA) suggest adjusting therapy every 3-6 months for pts who fail to achieve a disease activity target. However, pts…
Abstract Number: 75 • ACR/ARHP Annual Meeting 2012
Patient-Reported Outcomes Associated with Achieving and Maintaining Low Disease Activity in Rheumatoid Arthritis
Martin J. Bergman¹, James W. Shaw², Mary Cifaldi³, Gourab De⁴, Tony He⁵, Rajeev Ayyagari⁵ and James Signorovitch⁵, ¹Taylor Hospital, Ridley Park, PA, ²Global Health Economics and Outcomes Research, Abbott Laboratories, Abbott Park, IL, ³Abbott Laboratories, Abbott Park, IL, ⁴Analysis Group, Inc., New York, NY, ⁵Analysis Group, Inc., Boston, MA
Background/Purpose: Treat-to-target (T2T) guidelines for rheumatoid arthritis (RA) recognize low disease activity (LDA) as an acceptable therapeutic goal, particularly in patients with longstanding disease. The…